Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Chemo after complete surgical removal of local or regional breast cancer recurrence increases survival rates

SABCS 2012

Published: 6 Dec 2012

Views: 4221

Rating:

Save

Dr Stefan Aebi - Luzerner Kantonsspital, Luzern, Switzerland

Chemotherapy after surgery, or adjuvant chemotherapy, led to higher rates of disease-free and overall survival for women with isolated local or regional recurrence of breast cancer, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

Related Videos

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours

Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )

Breast Cancer

Dr Nita Nair - Apollo Cancer Centres, Mumbai

Breast Cancer ( Dr Nita Nair - Apollo Cancer Centres, Mumbai )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

More from ecancer